Multiple myeloma-New treatments 11/10/2026
1. Major phase 3 myeloma results: teclistamab + talquetamab
Johnson & Johnson announced positive phase 3 results for the combination of teclistamab (Tecvayli) and talquetamab (Talvey) in relapsed/refractory multiple myeloma.
Combines BCMA and GPRC5D targeting
Studied as early as second-line treatment
Company reports reduced disease progression and death risk compared with standard care
Detailed efficacy and safety results are expected at ASH 2026
Why it matters: Dual-target bispecific therapy could potentially move earlier in the myeloma treatment algorithm. We still need the absolute PFS benefit, toxicity data, and mature overall survival results. But these results are exciting


Comments